Aquaporin A/S holds a unique and strong IP position in the field of biomimetic membrane materials.

The patent portfolio holds 15 fully Aquaporin owned patent families and one patent family jointly owned with Nanyang Technological University, Singapore.

Aquaporin A/S has four granted European patents and three granted US patents. In total, 84 patents have been granted worldwide, while 48 applications are still pending, including one international stage application.

The patent rights give protection on membrane design and incorporation of membranes in industrial standard form factors as well as unique systems and uses of the Aquaporin Inside® technology in technical fields spanning from production of ultrapure water, diluted liquid fertilizer, treatment of industrial wastewater, generation of salinity power, and uses within hemodialysis and hemofiltration.

Our patent filing strategy is the highly useful combination of securing a fast national Danish patent right while pursuing international rights mainly through PCT applications, giving the company the possibility of obtaining patent rights in up to around 150 countries worldwide.

Aquaporin Inside® and our logo are established trademarks registered in the EU and the USA as well as being registered or pending in other important markets.

Patent Overview

The Aquaporin Inside® technology, including stabilization of aquaporin proteins, incorporation into vesicles, integration of stabilized aquaporin proteins and vesicles incorporating aquaporins in a thin film composite (TFC) layer, modification of flat sheet membranes or hollow fiber membranes modified with a TFC layer incorporating aquaporin proteins, preparation of modules comprising the flat sheet membranes or hollow fiber membranes, and various applications of these membranes or membrane modules, are protected by one or more of the patents or patent applications mentioned below:

WO06122566 A2 ; AU2006246841 (C1)  ; CA2607371 (C)  ; EP1885477 (B1)  ; EP2179780 (B1)  ; HK1109357 (A1)  ; HK1139890 (A1)  ; IN4455/KOLNP/2007 ; IL187164 (A)  ; JP5468253 (B2)  ; JP5616396 (B2)  ; NO341148 (B1)  ; US7857978 (B2)   ; WO07033675 A1 ; AU2006294205 (B2)  ; CA2621807 (C)  ; EP1937395 (B1)  ; IN258338 ; IL190074 (A)   ; JP5394466 (B2)  ; JP5627749 (B2)   ; NO341122 (B1)  ; US8123948 (B2)   ; DK177144 (B1)   ; WO10146365 A1 ; AU2010261557 (B2)   ; BR1011801-2 ; CA2765768 (A1)  ; CN102802770 (B)   ; EP2442894 (A1)   ; EP2977097 (A1)  ; IN216936 ; JP5690821 (B2)   ; SG176832 (A1)   ; KR20120050970 (A)  ; US2013277307 (A1)  ; US2015360183 (A1)  ; DK177307 (B1)  ; WO12080946 A1 ; AU2011342819 (B2)  ; BR1120130131250 ; CA2818230 (A1)  ; CN103402612 (B)  ; EP2651542 (B1)   ; IN1458/KOLNP/2013 ; IL226315 (A)  ; JP5889913 (B2)   ; SG191018 (A1)   ; KR20130140049 (A)  ; TWI524921 (B)   ; US9278316 (B2)   ; WO13043118 A1 ; TWI561294 (B)   ; EP2758156 (A1)  ; SG11201400825X (A)  ; CN104144737 (B)  ; US2014332468 (A1)  ; DK177840 (B1)  ; KR20-0477157 ; TW201440881 (A)  ; AU2014206128 (C1)  ; BR1120150159850 ; CA2897354 (A1)   ; EP2943270 (A1)   ; HK1217007 (A1)  ; IN239703 ; 239703 ; JP5946591 (B2)  ; JP6141487 (B2)   ; SG11201504700R (A)   ; SG10201604075S (A)  ; US2015144553 (A1) ; WO14128293 A1 ; TW201446658 (A)  ; CA2901020 (A1)  ; CN105026017 (B) ; EP2958662 (A1)   ; HK1218408 (A1) ; IL240101 ; IN2253/KOLNP/2015 ; JP2016514039 (A)   ; KR20150120978 (A)  ; US2016016127 (A1)   ; DK178227 (B1)  ; WO15166038 A1 ; TW201602177 (A)   ; DK179128 ; WO 2015/124716 ; EP3110532 (A1) ; US2017/0065762 ; CN106573094 ; WO17137361 A1 ; DK PA 2017 70753